A Comprehensive Overview of the Antibiotics Approved in the Last Two Decades: Retrospects and Prospects

Due to the overuse of antibiotics, bacterial resistance has markedly increased to become a global problem and a major threat to human health. Fortunately, in recent years, various new antibiotics have been developed through both improvements to traditional antibiotics and the discovery of antibiotics with novel mechanisms with the aim of addressing the decrease in the efficacy of traditional antibiotics. This manuscript reviews the antibiotics that have been approved for marketing in the last 20 years with an emphasis on the antibacterial properties, mechanisms, structure–activity relationships (SARs), and clinical safety of these antibiotics. Furthermore, the current deficiencies, opportunities for improvement, and prospects of antibiotics are thoroughly discussed to provide new insights for the design and development of safer and more potent antibiotics.

[1]  Yulin Zhang,et al.  Synergistic Activity of Imipenem in Combination with Ceftazidime/Avibactam or Avibactam against Non-MBL-Producing Extensively Drug-Resistant Pseudomonas aeruginosa , 2022, Microbiology spectrum.

[2]  R. Kale,et al.  Design and synthesis of an oral prodrug alalevonadifloxacin for the treatment of MRSA infection. , 2021, Bioorganic & medicinal chemistry letters.

[3]  Sheridan M. Hoy Contezolid: First Approval , 2021, Drugs.

[4]  Arnold Lee Ibrexafungerp: First Approval , 2021, Drugs.

[5]  Qianqian Zhao,et al.  Current Landscape and Future Perspective of Oxazolidinone Scaffolds Containing Antibacterial Drugs. , 2021, Journal of medicinal chemistry.

[6]  A. Scala,et al.  Oxazolidinone Antibiotics: Chemical, Biological and Analytical Aspects , 2021, Molecules.

[7]  R. Chai,et al.  Mechanism and Prevention of Ototoxicity Induced by Aminoglycosides , 2021, Frontiers in Cellular Neuroscience.

[8]  R. Echols,et al.  Comment on ‘Cefiderocol, a New Siderophore Cephalosporin for the Treatment of Complicated Urinary Tract Infections Caused by Multidrug-resistant Pathogens: Preclinical and Clinical Pharmacokinetics, Pharmacodynamics, Efficacy and Safety’ , 2021, Clinical Drug Investigation.

[9]  A. Atilgan,et al.  A trimethoprim derivative impedes antibiotic resistance evolution , 2021, Nature Communications.

[10]  H. Bax,et al.  New-Generation Antibiotics for Treatment of Gram-Positive Infections: A Review with Focus on Endocarditis and Osteomyelitis , 2021, Journal of clinical medicine.

[11]  Raj Kumar,et al.  U.S. FDA Approved Drugs from 2015-June 2020: A Perspective. , 2021, Journal of medicinal chemistry.

[12]  X. Hou,et al.  Nanohole-boosted electron transport between nanomaterials and bacteria as a concept for nano–bio interactions , 2021, Nature communications.

[13]  P. Cos,et al.  The search for novel treatment strategies for Streptococcus pneumoniae infections , 2021, FEMS microbiology reviews.

[14]  L. Mandell,et al.  Lefamulin: A Novel Oral and Intravenous Pleuromutilin for the Treatment of Community-Acquired Bacterial Pneumonia , 2020, Drugs.

[15]  F. Kong,et al.  Antimicrobial activity of omadacycline in vitro against bacteria isolated from 2014 to 2017 in China, a multi-center study , 2020, BMC microbiology.

[16]  N. Razzaghi-Asl,et al.  Synthesis and biological assessment of ciprofloxacin-derived 1,3,4-thiadiazoles as anticancer agents. , 2020, Bioorganic chemistry.

[17]  W. Ang,et al.  “Illuminating” Echinocandins’ Mechanism of Action , 2020, ACS central science.

[18]  I. Lomakin,et al.  Sarecycline interferes with tRNA accommodation and tethers mRNA to the 70S ribosome , 2020, Proceedings of the National Academy of Sciences.

[19]  Shengzheng Wang,et al.  Recent Progress in the Discovery of Antifungal Agents Targeting the Cell Wall. , 2020, Journal of medicinal chemistry.

[20]  T. Velkov,et al.  Structure-activity relationships of daptomycin lipopeptides. , 2020, Journal of medicinal chemistry.

[21]  A. Velayati,et al.  Caspofungin: a review of its characteristics, activity, and use in intensive care units , 2020, Expert review of anti-infective therapy.

[22]  S. Singh,et al.  Lascufloxacin hydrochloride to treat bacterial infection. , 2020, Drugs of today.

[23]  A. Rubio,et al.  In Vitro and In Vivo Characterization of Tebipenem, an Oral Carbapenem , 2020, Antimicrobial Agents and Chemotherapy.

[24]  T. Lithgow,et al.  Characterization of the Core Ribosomal Binding Region for the Oxazolidone Family of Antibiotics Using Cryo-EM. , 2020, ACS pharmacology & translational science.

[25]  Karthik Gunasekaran,et al.  Levonadifloxacin, a recently approved benzoquinolizine fluoroquinolone, exhibits potent in vitro activity against contemporary Staphylococcus aureus isolates and Bengal Bay clone isolates collected from a large Indian tertiary care hospital. , 2020, The Journal of antimicrobial chemotherapy.

[26]  Li Li,et al.  Population Pharmacokinetics Study of Contezolid (MRX-I), a Novel Oxazolidinone Antibacterial Agent, in Chinese Patients. , 2020, Clinical therapeutics.

[27]  R. Montelaro,et al.  Enhanced therapeutic index of an antimicrobial peptide in mice by increasing safety and activity against multidrug-resistant bacteria , 2020, Science Advances.

[28]  H. Sahl,et al.  Ca2+-Daptomycin targets cell wall biosynthesis by forming a tripartite complex with undecaprenyl-coupled intermediates and membrane lipids , 2020, Nature Communications.

[29]  M. Chorilli,et al.  Biological Properties and Analytical Methods for Micafungin: A Critical Review , 2020, Critical reviews in analytical chemistry.

[30]  M. Bassetti,et al.  The interplay between acute bacterial skin and skin structure infections and depression: a vicious circle of major clinical importance. , 2020, Current opinion in infectious diseases.

[31]  Denice C. Bay,et al.  Omadacycline: A Novel Oral and Intravenous Aminomethylcycline Antibiotic Agent , 2020, Drugs.

[32]  R. Grimalt,et al.  Ozenoxacin, a New Effective and Safe Topical Treatment for Impetigo in Children and Adolescents , 2020, Dermatology.

[33]  Guang-Ji Wang,et al.  Mechanisms and pharmacokinetic/pharmacodynamic profiles underlying the low nephrotoxicity and ototoxicity of etimicin , 2020, Acta Pharmacologica Sinica.

[34]  G. Zhanel,et al.  A Dimer, but Not Monomer, of Tobramycin Potentiates Ceftolozane against Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa and Delays Resistance Development , 2020, Antimicrobial Agents and Chemotherapy.

[35]  J. Tour,et al.  Molecular Nanomachines Disrupt Bacterial Cell Wall, Increasing Sensitivity of Extensively Drug-Resistant Klebsiella pneumoniae to Meropenem , 2019, ACS nano.

[36]  R. Echols,et al.  Pharmacokinetic and Pharmacodynamic Profiles of Cefiderocol, a Novel Siderophore Cephalosporin , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[37]  K. Kazmierczak,et al.  In vitro activity of imipenem-relebactam and key β-lactam agents against Gram-negative bacilli isolated from lower respiratory tract infection samples of intensive care unit patients - SMART Surveillance United States 2015-2017. , 2019, International journal of antimicrobial agents.

[38]  B. Wilkinson,et al.  Antibiotics: past, present and future. , 2019, Current opinion in microbiology.

[39]  H. A. Farrag,et al.  Natural outer membrane permeabilizers boost antibiotic action against irradiated resistant bacteria , 2019, Journal of Biomedical Science.

[40]  R. Bonomo,et al.  Evaluation of in vitro activity of ceftazidime/avibactam and ceftolozane/tazobactam against MDR Pseudomonas aeruginosa isolates from Qatar. , 2019, The Journal of antimicrobial chemotherapy.

[41]  Xiaojie Li,et al.  Coagulation factors VII, IX and X are effective antibacterial proteins against drug-resistant Gram-negative bacteria , 2019, Cell Research.

[42]  P. Eckburg,et al.  Omadacycline for Acute Bacterial Skin and Skin Structure Infections , 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[43]  J. Marty,et al.  Optical and Electrochemical Sensors and Biosensors for the Detection of Quinolones. , 2019, Trends in biotechnology.

[44]  Milad Iranshahy,et al.  Review on plant antimicrobials: a mechanistic viewpoint , 2019, Antimicrobial Resistance & Infection Control.

[45]  C. Chao,et al.  The Efficacy and Safety of Eravacycline in the Treatment of Complicated Intra-Abdominal Infections: A Systemic Review and Meta-Analysis of Randomized Controlled Trials , 2019, Journal of clinical medicine.

[46]  M. McCarthy Clinical Pharmacokinetics and Pharmacodynamics of Eravacycline , 2019, Clinical Pharmacokinetics.

[47]  Durães,et al.  Omadacycline: A Newly Approved Antibacterial from the Class of Tetracyclines , 2019, Pharmaceuticals.

[48]  Hongfen Yang,et al.  Recent Progress in Natural-Product-Inspired Programs Aimed To Address Antibiotic Resistance and Tolerance. , 2019, Journal of medicinal chemistry.

[49]  Jian Sun,et al.  A Genomic, Evolutionary, and Mechanistic Study of MCR‐5 Action Suggests Functional Unification across the MCR Family of Colistin Resistance , 2019, Advanced science.

[50]  K. Rodvold Introduction: lefamulin and pharmacokinetic/pharmacodynamic rationale to support the dose selection of lefamulin , 2019, The Journal of antimicrobial chemotherapy.

[51]  S. Gelone,et al.  Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia , 2019, The Journal of antimicrobial chemotherapy.

[52]  J. Vila,et al.  Ozenoxacin: a review of preclinical and clinical efficacy , 2019, Expert review of anti-infective therapy.

[53]  P. Eckburg,et al.  Omadacycline for Community‐Acquired Bacterial Pneumonia , 2019, The New England journal of medicine.

[54]  J. Karlowsky,et al.  Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli , 2019, Drugs.

[55]  E. Deeks Sarecycline: First Global Approval , 2019, Drugs.

[56]  A. Mehta,et al.  Cutaneous Complications in Recipients of Lung Transplants: A Pictorial Review. , 2019, Chest.

[57]  B. Sankaran,et al.  Differential active site requirements for NDM-1 β-lactamase hydrolysis of carbapenem versus penicillin and cephalosporin antibiotics , 2018, Nature Communications.

[58]  S. Flanagan,et al.  Use of Translational Pharmacokinetic/Pharmacodynamic Infection Models To Understand the Impact of Neutropenia on the Efficacy of Tedizolid Phosphate , 2018, Antimicrobial Agents and Chemotherapy.

[59]  R. Hall,et al.  An evaluation of tedizolid for the treatment of MRSA infections , 2018, Expert opinion on pharmacotherapy.

[60]  A. Mankin,et al.  How Macrolide Antibiotics Work. , 2018, Trends in biochemical sciences.

[61]  M. Veve,et al.  Lefamulin: Review of a Promising Novel Pleuromutilin Antibiotic , 2018, Pharmacotherapy.

[62]  Li Cai,et al.  Crystal structure of tebipenem pivoxil , 2018, Acta crystallographica. Section E, Crystallographic communications.

[63]  Sohita Dhillon Meropenem/Vaborbactam: A Review in Complicated Urinary Tract Infections , 2018, Drugs.

[64]  M. Pucci,et al.  Tebipenem, the first oral carbapenem antibiotic , 2018, Expert review of anti-infective therapy.

[65]  T. Wencewicz,et al.  Tetracycline-Inactivating Enzymes , 2018, Front. Microbiol..

[66]  P. Stogios,et al.  Plazomicin Retains Antibiotic Activity against Most Aminoglycoside Modifying Enzymes. , 2018, ACS infectious diseases.

[67]  R. Ebright,et al.  Structural Basis of Transcription Inhibition by Fidaxomicin (Lipiarmycin A3). , 2018, Molecular cell.

[68]  S. Paukner,et al.  In Vitro Activity of Lefamulin against Sexually Transmitted Bacterial Pathogens , 2018, Antimicrobial Agents and Chemotherapy.

[69]  A. Cheng,et al.  Mind Your Ears: A New Antidote to Aminoglycoside Toxicity? , 2018, Journal of medicinal chemistry.

[70]  Kevin Braeckmans,et al.  Nanomaterials and molecular transporters to overcome the bacterial envelope barrier: Towards advanced delivery of antibiotics , 2017, Advanced drug delivery reviews.

[71]  A. Minami,et al.  Biosynthetic Machinery of Diterpene Pleuromutilin Isolated from Basidiomycete Fungi , 2017, Chembiochem : a European journal of chemical biology.

[72]  M. Hackel,et al.  In Vitro Activity of Meropenem-Vaborbactam against Clinical Isolates of KPC-Positive Enterobacteriaceae , 2017, Antimicrobial Agents and Chemotherapy.

[73]  A. Caffrey,et al.  Thrombocytopenia with Tedizolid and Linezolid , 2017, Antimicrobial Agents and Chemotherapy.

[74]  Tianfeng Chen,et al.  Modified Penicillin Molecule with Carbapenem-Like Stereochemistry Specifically Inhibits Class C β-Lactamases , 2017, Antimicrobial Agents and Chemotherapy.

[75]  R. MacLaren,et al.  Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study , 2017, Annals of Clinical Microbiology and Antimicrobials.

[76]  A. Markham Delafloxacin: First Global Approval , 2017, Drugs.

[77]  M. Hackel,et al.  In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against a Recent Collection of Clinically Relevant Gram-Negative Bacilli from North America and Europe, Including Carbapenem-Nonsusceptible Isolates (SIDERO-WT-2014 Study) , 2017, Antimicrobial Agents and Chemotherapy.

[78]  D. Fairlie,et al.  Orally Absorbed Cyclic Peptides. , 2017, Chemical reviews.

[79]  M. El-Gamal,et al.  Recent updates of carbapenem antibiotics. , 2017, European journal of medicinal chemistry.

[80]  I. Schalk,et al.  Bacterial Iron Uptake Pathways: Gates for the Import of Bactericide Compounds. , 2017, Journal of medicinal chemistry.

[81]  M. Richards,et al.  Demonstrating the Protective Efficacy of the Novel Fluoroquinolone Finafloxacin against an Inhalational Exposure to Burkholderia pseudomallei , 2017, Antimicrobial Agents and Chemotherapy.

[82]  Yahong Liu,et al.  Design, synthesis and antibacterial evaluation of novel pleuromutilin derivatives possessing piperazine linker. , 2017, European journal of medicinal chemistry.

[83]  D. Andes,et al.  In Vivo Pharmacodynamic Evaluation of Omadacycline (PTK 0796) against Streptococcus pneumoniae in the Murine Pneumonia Model , 2017, Antimicrobial Agents and Chemotherapy.

[84]  Ximing Xu,et al.  Synthesis and antibacterial activities of novel pleuromutilin derivatives with a substituted pyrimidine moiety. , 2017, European journal of medicinal chemistry.

[85]  H. Schweizer,et al.  Finafloxacin overcomes Burkholderia pseudomallei efflux-mediated fluoroquinolone resistance , 2016, The Journal of antimicrobial chemotherapy.

[86]  L. Scott Ceftaroline Fosamil: A Review in Complicated Skin and Soft Tissue Infections and Community-Acquired Pneumonia , 2016, Drugs.

[87]  H. Yoshizawa,et al.  Siderophore Cephalosporin Cefiderocol Utilizes Ferric Iron Transporter Systems for Antibacterial Activity against Pseudomonas aeruginosa , 2016, Antimicrobial Agents and Chemotherapy.

[88]  Sungkyoung Lee,et al.  Fluoroquinolone resistance of Streptococcus pneumoniae isolates causing invasive disease: special focus on zabofloxacin. , 2016, Diagnostic microbiology and infectious disease.

[89]  Ronald N. Jones,et al.  Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae , 2016, Antimicrobial Agents and Chemotherapy.

[90]  D. Szabo,et al.  Chemical structure and pharmacokinetics of novel quinolone agents represented by avarofloxacin, delafloxacin, finafloxacin, zabofloxacin and nemonoxacin , 2016, Annals of Clinical Microbiology and Antimicrobials.

[91]  R. Bonomo,et al.  Treatment options for infections caused by carbapenem-resistant Enterobacteriaceae: can we apply “precision medicine” to antimicrobial chemotherapy? , 2016, Expert opinion on pharmacotherapy.

[92]  J. Karlowsky,et al.  Review of Eravacycline, a Novel Fluorocycline Antibacterial Agent , 2016, Drugs.

[93]  J. Pagés,et al.  Role of the Outer Membrane and Porins in Susceptibility of β-Lactamase-Producing Enterobacteriaceae to Ceftazidime-Avibactam , 2015, Antimicrobial Agents and Chemotherapy.

[94]  Akinobu Ito,et al.  In Vitro Antimicrobial Activity of a Siderophore Cephalosporin, S-649266, against Enterobacteriaceae Clinical Isolates, Including Carbapenem-Resistant Strains , 2015, Antimicrobial Agents and Chemotherapy.

[95]  A. Bolger,et al.  Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association , 2015, Circulation.

[96]  S. Levy,et al.  Structure-Activity Relationship of the Aminomethylcyclines and the Discovery of Omadacycline , 2015, Antimicrobial Agents and Chemotherapy.

[97]  M. Mahoney,et al.  Ceftolozane/tazobactam and ceftazidime/avibactam: two novel β-lactam/β-lactamase inhibitor combination agents for the treatment of resistant Gram-negative bacterial infections. , 2015, International journal of antimicrobial agents.

[98]  R. Frykberg,et al.  Linezolid-Associated Serotonin Syndrome. A Report of Two Cases. , 2015, Journal of the American Podiatric Medical Association.

[99]  S. Burdette,et al.  Tedizolid: The First Once-Daily Oxazolidinone Class Antibiotic. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[100]  H. Schweizer,et al.  Efflux pump-mediated drug resistance in Burkholderia , 2015, Front. Microbiol..

[101]  Craig A. Martin,et al.  Early Experience with Tedizolid: Clinical Efficacy, Pharmacodynamics, and Resistance , 2014, Pharmacotherapy.

[102]  G. Poce,et al.  SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development. , 2014, European journal of medicinal chemistry.

[103]  Cheng‐He Zhou,et al.  Novel hybrids of metronidazole and quinolones: synthesis, bioactive evaluation, cytotoxicity, preliminary antimicrobial mechanism and effect of metal ions on their transportation by human serum albumin. , 2014, European journal of medicinal chemistry.

[104]  S. Gropper,et al.  Ozenoxacin 1% cream in the treatment of impetigo: a multicenter, randomized, placebo- and retapamulin-controlled clinical trial. , 2014, Future microbiology.

[105]  Ronald N. Jones,et al.  Comparison of EUCAST and CLSI broth microdilution methods for the susceptibility testing of 10 systemically active antifungal agents when tested against Candida spp. , 2014, Diagnostic microbiology and infectious disease.

[106]  Zhengyu Yuan,et al.  New potent antibacterial oxazolidinone (MRX-I) with an improved class safety profile. , 2014, Journal of medicinal chemistry.

[107]  T. Wichelhaus,et al.  Novel promising linezolid analogues: rational design, synthesis and biological evaluation. , 2013, European journal of medicinal chemistry.

[108]  D. Fong,et al.  Prospects for circumventing aminoglycoside kinase mediated antibiotic resistance , 2013, Front. Cell. Infect. Microbiol..

[109]  Han Liu,et al.  Total synthesis of daptomycin by cyclization via a chemoselective serine ligation. , 2013, Journal of the American Chemical Society.

[110]  Ronald N. Jones,et al.  Activity of MK-3118, a new oral glucan synthase inhibitor, tested against Candida spp. by two international methods (CLSI and EUCAST). , 2013, The Journal of antimicrobial chemotherapy.

[111]  J. Karlowsky,et al.  Ceftazidime-Avibactam: a Novel Cephalosporin/β-lactamase Inhibitor Combination , 2013, Drugs.

[112]  D. Shlaes New β‐lactam–β‐lactamase inhibitor combinations in clinical development , 2013, Annals of the New York Academy of Sciences.

[113]  L. Mandell Gemifloxacin , 2020, Drugs.

[114]  Ronald N. Jones,et al.  In Vitro Activity of a New Oral Glucan Synthase Inhibitor (MK-3118) Tested against Aspergillus spp. by CLSI and EUCAST Broth Microdilution Methods , 2012, Antimicrobial Agents and Chemotherapy.

[115]  S. Kondo,et al.  Efficacy and safety of garenoxacin in the treatment of upper respiratory tract infections. , 2012, Auris, nasus, larynx.

[116]  Heping Yang,et al.  Prulifloxacin versus Levofloxacin in the Treatment of Respiratory and Urinary Tract Infections: A Multicentre, Double-Blind, Randomized Controlled Clinical Trial , 2012, Chemotherapy.

[117]  Ronald N. Jones,et al.  Disk Diffusion and MIC Quality Control Ranges for BC-3205 and BC-3781, Two Novel Pleuromutilin Antibiotics , 2012, Journal of Clinical Microbiology.

[118]  Ronald N. Jones,et al.  Antimicrobial activity of the novel pleuromutilin antibiotic BC-3781 against organisms responsible for community-acquired respiratory tract infections (CARTIs). , 2012, The Journal of antimicrobial chemotherapy.

[119]  Nicola G. Jones,et al.  Synthesis and Structure − Activity Relationships of New Quinolone-Type Molecules against Trypanosoma brucei , 2012 .

[120]  M. Rönn,et al.  Fluorocyclines. 1. 7-fluoro-9-pyrrolidinoacetamido-6-demethyl-6-deoxytetracycline: a potent, broad spectrum antibacterial agent. , 2012, Journal of medicinal chemistry.

[121]  Z. Aktaş,et al.  In vitro activity of avibactam (NXL104) in combination with β-lactams against Gram-negative bacteria, including OXA-48 β-lactamase-producing Klebsiella pneumoniae. , 2012, International journal of antimicrobial agents.

[122]  J. Karlowsky,et al.  Comparative Review of the Carbapenems , 2012, Drugs.

[123]  L. Scott,et al.  Besifloxacin Ophthalmic Suspension 0.6% , 2012, Drugs.

[124]  A. Mahmoud,et al.  Chapter 4 – Gemifloxacin , 2011 .

[125]  C. Shim,et al.  Fluorescence detection of Zabofloxacin, a novel fluoroquinolone antibiotic, in plasma, bile, and urine by HPLC: the first oral and intravenous applications in a pharmacokinetic study in rats. , 2011, Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques.

[126]  A. Tolmachev,et al.  Bicyclic conformationally restricted diamines. , 2011, Chemical reviews.

[127]  F. Goh,et al.  In Vitro Spectrum of Activity of Finafloxacin, a Novel, pH-Activated Fluoroquinolone, under Standard and Acidic Conditions , 2011, Antimicrobial Agents and Chemotherapy.

[128]  E. Goldstein,et al.  Activity of garenoxacin against 536 unusual anaerobes including 128 recovered from acute pelvic infections. , 2011, Diagnostic microbiology and infectious disease.

[129]  M. Falagas,et al.  Prulifloxacin: a review focusing on its use beyond respiratory and urinary tract infections. , 2011, International journal of antimicrobial agents.

[130]  C. Hutnik,et al.  Besifloxacin Ophthalmic Suspension: Emerging Evidence of its Therapeutic Value in Bacterial Conjunctivitis , 2011, Ophthalmology and eye diseases.

[131]  E. Chahine,et al.  Doripenem: a new carbapenem antibiotic. , 2010, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[132]  Honggang Hu,et al.  Synthesis and antifungal evaluation of novel triazole derivatives as inhibitors of cytochrome P450 14alpha-demethylase. , 2010, European journal of medicinal chemistry.

[133]  L. A. Feeney,et al.  Synthesis and Spectrum of the Neoglycoside ACHN-490 , 2010, Antimicrobial Agents and Chemotherapy.

[134]  Lian-Shun Feng,et al.  Synthesis and in vitro antimycobacterial activity of balofloxacin ethylene isatin derivatives. , 2010, European journal of medicinal chemistry.

[135]  Hee-Soo Park,et al.  DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae. , 2010, International journal of antimicrobial agents.

[136]  Steven D. Brown,et al.  Comparative In Vitro Antimicrobial Activities of Torezolid (TR-700), the Active Moiety of a New Oxazolidinone, Torezolid Phosphate (TR-701), Determination of Tentative Disk Diffusion Interpretive Criteria, and Quality Control Ranges , 2010, Antimicrobial Agents and Chemotherapy.

[137]  L. Xiao-dong,et al.  The influence of a newly developed quinolone: Antoflox-acin, on CYP activity in rats , 2010, European Journal of Drug Metabolism and Pharmacokinetics.

[138]  D. Hoban,et al.  In Vitro Activity of Nemonoxacin, a Novel Nonfluorinated Quinolone, against 2,440 Clinical Isolates , 2009, Antimicrobial Agents and Chemotherapy.

[139]  C. Liao,et al.  Comparative in vitro activities of the new quinolone nemonoxacin (TG-873870), gemifloxacin and other quinolones against clinical isolates of Mycobacterium tuberculosis. , 2009, The Journal of antimicrobial chemotherapy.

[140]  Yong-hong Xiao,et al.  Pharmacokinetics/pharmacodynamics of antofloxacin hydrochloride in a neutropenic murine thigh model of Staphylococcus aureus infection , 2008, Acta Pharmacologica Sinica.

[141]  L. Piddock,et al.  The Efflux Pump Inhibitor Reserpine Selects Multidrug-Resistant Streptococcus pneumoniae Strains That Overexpress the ABC Transporters PatA and PatB , 2008, Antimicrobial Agents and Chemotherapy.

[142]  S. Deresinski,et al.  Reviews of anti-infective agents: posaconazole: a broad-spectrum triazole antifungal agent. , 2007, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[143]  D. Guay,et al.  Update on clindamycin in the management of bacterial, fungal and protozoal infections , 2007, Expert opinion on pharmacotherapy.

[144]  Daryl S Schiller,et al.  Posaconazole: an extended-spectrum triazole antifungal agent. , 2007, Clinical therapeutics.

[145]  Myung G. Lee,et al.  Pharmacokinetics of DA‐7218, a new oxazolidinone, and its active metabolite, DA‐7157, after intravenous and oral administration of DA‐7218 and DA‐7157 to rats , 2007, The Journal of pharmacy and pharmacology.

[146]  K. Ward,et al.  Nonclinical pharmacodynamics, pharmacokinetics, and safety of BOL-303224-A, a novel fluoroquinolone antimicrobial agent for topical ophthalmic use. , 2007, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.

[147]  A. Kwon,et al.  In vitro and in vivo activities of DW-224a, a novel fluoroquinolone antibiotic agent. , 2006, The Journal of antimicrobial chemotherapy.

[148]  J. Sobel,et al.  Anidulafungin: a novel echinocandin. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[149]  Ronald N. Jones,et al.  Activity of Retapamulin (SB-275833), a Novel Pleuromutilin, against Selected Resistant Gram-Positive Cocci , 2006, Antimicrobial Agents and Chemotherapy.

[150]  Hee-Soo Park,et al.  In Vitro and In Vivo Antibacterial Activities of DW-224a, a New Fluoronaphthyridone , 2006, Antimicrobial Agents and Chemotherapy.

[151]  M. Jacobs,et al.  Activity of Retapamulin against Streptococcus pyogenes and Staphylococcus aureus Evaluated by Agar Dilution, Microdilution, E-Test, and Disk Diffusion Methodologies , 2006, Antimicrobial Agents and Chemotherapy.

[152]  M. Pfaller,et al.  Activities of Micafungin against 315 Invasive Clinical Isolates of Fluconazole-Resistant Candida spp , 2006, Journal of Clinical Microbiology.

[153]  Telithromycin: A Possible Cause of Severe Liver Damage? , 2006, Annals of Internal Medicine.

[154]  M. Cazzola,et al.  Prulifloxacin: a new fluoroquinolone for the treatment of acute exacerbation of chronic bronchitis. , 2006, Pulmonary pharmacology & therapeutics.

[155]  J. Schrenzel,et al.  Intensive Therapy with Ceftobiprole Medocaril of Experimental Foreign-Body Infection by Methicillin-Resistant Staphylococcus aureus , 2005, Antimicrobial Agents and Chemotherapy.

[156]  C. Perry,et al.  Caspofungin: a review of its use in the treatment of fungal infections. , 2005, Drugs.

[157]  Ronald N. Jones,et al.  Activities of Doripenem (S-4661) against Drug-Resistant Clinical Pathogens , 2004, Antimicrobial Agents and Chemotherapy.

[158]  B. Yoo,et al.  Gemifloxacin: A New Fluoroquinolone Approved for Treatment of Respiratory Infections , 2004, The Annals of pharmacotherapy.

[159]  A. Rodloff,et al.  In Vitro Activity of OPT-80 against Clostridium difficile , 2004, Antimicrobial Agents and Chemotherapy.

[160]  C. Carpenter,et al.  Daptomycin: another novel agent for treating infections due to drug-resistant gram-positive pathogens. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[161]  B. Bozdoğan,et al.  Oxazolidinones: activity, mode of action, and mechanism of resistance. , 2004, International journal of antimicrobial agents.

[162]  T. Ishikawa,et al.  In vitro antimicrobial activity of T-91825, a novel anti-MRSA cephalosporin, and in vivo anti-MRSA activity of its prodrug, TAK-599 , 2004, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[163]  Y. Ikeda,et al.  TAK-599, a novel N-phosphono type prodrug of anti-MRSA cephalosporin T-91825: synthesis, physicochemical and pharmacological properties. , 2003, Bioorganic & medicinal chemistry.

[164]  C. Perry,et al.  Ertapenem: a review of its use in the management of bacterial infections. , 2003, Drugs.

[165]  C. Perry,et al.  Biapenem. , 2020, Drugs.

[166]  M. Takahata,et al.  Synthesis, antibacterial activity, and toxicity of 7-(isoindolin-5-yl)-4-oxoquinoline-3-carboxylic acids. Discovery of the novel des-F(6)-quinolone antibacterial agent garenoxacin (T-3811 or BMS-284756). , 2011, Arzneimittel-Forschung.

[167]  J. Iqbal,et al.  Synthesis of conformationally constrained analogues of linezolid: structure-activity relationship (SAR) studies on selected novel tricyclic oxazolidinones. , 2002, Journal of medicinal chemistry.

[168]  K. Hayashi,et al.  In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. , 2002, The Journal of antimicrobial chemotherapy.

[169]  Y. Kawai,et al.  Photochemical behavior of sitafloxacin, fluoroquinolone antibiotic, in an aqueous solution. , 2002, Chemical & pharmaceutical bulletin.

[170]  Antoine Andremont,et al.  Bronchopulmonary Disposition of the Ketolide Telithromycin (HMR 3647) , 2001, Antimicrobial Agents and Chemotherapy.

[171]  Marilyn Roberts,et al.  Tetracycline Antibiotics: Mode of Action, Applications, Molecular Biology, and Epidemiology of Bacterial Resistance , 2001, Microbiology and Molecular Biology Reviews.

[172]  E Rubinstein,et al.  Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study. , 2001, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[173]  R. Jelliffe,et al.  Comparative Pharmacokinetics and Pharmacodynamics of the Newer Fluoroquinolone Antibacterials , 2001, Clinical pharmacokinetics.

[174]  H. Nagare,et al.  [In vitro antimycobacterial activities of a new quinolone, balofloxacin]. , 2001, Kekkaku : [Tuberculosis].

[175]  S. Douthwaite Structure-activity relationships of ketolides vs. macrolides. , 2001, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[176]  V. Ramakrishnan,et al.  The Structural Basis for the Action of the Antibiotics Tetracycline, Pactamycin, and Hygromycin B on the 30S Ribosomal Subunit , 2000, Cell.

[177]  T. Tamaya,et al.  In vitro and in vivo antibacterial activities of a new injectable carbapenem, S-4661, against gynaecological pathogens. , 2000, The Journal of antimicrobial chemotherapy.

[178]  H. Tomioka,et al.  Comparative Antimicrobial Activities of the Newly Synthesized Quinolone WQ-3034, Levofloxacin, Sparfloxacin, and Ciprofloxacin against Mycobacterium tuberculosis andMycobacterium avium Complex , 2000, Antimicrobial Agents and Chemotherapy.

[179]  R. Jones,et al.  Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. , 2000, Diagnostic microbiology and infectious disease.

[180]  M. Hikida,et al.  In Vitro Antibacterial Activity of LJC 11,036, an Active Metabolite of L-084, a New Oral Carbapenem Antibiotic with Potent Antipneumococcal Activity , 1999, Antimicrobial Agents and Chemotherapy.

[181]  A. Yamada,et al.  FK463, a novel water-soluble echinocandin lipopeptide: synthesis and antifungal activity. , 1999, The Journal of antibiotics.

[182]  Yasuo Watanabe,et al.  In Vitro and In Vivo Antimicrobial Activities of T-3811ME, a Novel Des-F(6)-Quinolone , 1999, Antimicrobial Agents and Chemotherapy.

[183]  N. Jacobus,et al.  In Vitro and In Vivo Antibacterial Activities of a Novel Glycylcycline, the 9-t-Butylglycylamido Derivative of Minocycline (GAR-936) , 1999, Antimicrobial Agents and Chemotherapy.

[184]  H. Narita,et al.  Pharmacological properties of T-3762, a novel fluoroquinolone antimicrobial agent in parenteral use. III. Chemical structures and dermovascular permeability-increasing activities. , 1998, Biological & pharmaceutical bulletin.

[185]  B. Pelak,et al.  In Vivo Activity and Pharmacokinetic Evaluation of a Novel Long-Acting Carbapenem Antibiotic, MK-826 (L-749,345) , 1998, Antimicrobial Agents and Chemotherapy.

[186]  Y. Kim,et al.  Novel fluoroquinolone antibacterial agents containing oxime-substituted (aminomethyl)pyrrolidines: synthesis and antibacterial activity of 7-(4-(aminomethyl)-3-(methoxyimino)pyrrolidin-1-yl)-1-cyclopropyl-6- fluoro-4-oxo-1,4-dihydro[1,8]naphthyridine-3-carboxylic acid (LB20304). , 1997, Journal of medicinal chemistry.

[187]  J. Sobel,et al.  In vitro activity of a new pneumocandin antifungal, L-743,872, against azole-susceptible and -resistant Candida species , 1997, Antimicrobial agents and chemotherapy.

[188]  J. Galgiani,et al.  In vitro studies of activities of the antifungal triazoles SCH56592 and itraconazole against Candida albicans, Cryptococcus neoformans, and other pathogenic yeasts , 1997, Antimicrobial agents and chemotherapy.

[189]  R. H. Baltz,et al.  Gene transfer and transposition mutagenesis in Streptomyces roseosporus: mapping of insertions that influence daptomycin or pigment production. , 1996, Microbiology.

[190]  M. Shaw,et al.  Semisynthetic echinocandins affect cell wall deposition of Pneumocystis carinii in vitro and in vivo , 1996, Antimicrobial agents and chemotherapy.

[191]  Steven D. Brown,et al.  In vitro studies of two triazole antifungal agents (voriconazole [UK-109,496] and fluconazole) against Candida species , 1996, Antimicrobial agents and chemotherapy.

[192]  S. J. Brickner,et al.  Synthesis and antibacterial activity of U-100592 and U-100766, two oxazolidinone antibacterial agents for the potential treatment of multidrug-resistant gram-positive bacterial infections. , 1996, Journal of medicinal chemistry.

[193]  A. Miyoshi,et al.  Reduced phototoxicity of a fluoroquinolone antibacterial agent with a methoxy group at the 8 position in mice irradiated with long-wavelength UV light , 1993, Antimicrobial Agents and Chemotherapy.

[194]  T. Nishino,et al.  In vivo evaluation of NM441, a new thiazeto-quinoline derivative , 1991, Antimicrobial Agents and Chemotherapy.

[195]  M. Debono,et al.  Deacylation of echinocandin B by Actinoplanes utahensis. , 1989, The Journal of antibiotics.

[196]  K. Thomson,et al.  Meropenem: activity against resistant gram-negative bacteria and interactions with beta-lactamases. , 1989, The Journal of antimicrobial chemotherapy.

[197]  F. Kayser,et al.  Activity of meropenem, against gram-positive bacteria. , 1989, The Journal of antimicrobial chemotherapy.

[198]  H. Egger,et al.  New pleuromutilin derivatives with enhanced antimicrobial activity.II.Structure-activity correlations. , 1976, The Journal of antibiotics.